Tofacitinib and metformin reduce the dermal thickness and fibrosis in mouse model of systemic sclerosis.

MLA

Karatas, Ahmet, et al. “Tofacitinib and Metformin Reduce the Dermal Thickness and Fibrosis in Mouse Model of Systemic Sclerosis.” Scientific Reports, vol. 12, no. 1, Feb. 2022, p. 2553. EBSCOhost, https://doi.org/10.1038/s41598-022-06581-1.

APA

Karatas, A., Oz, B., Celik, C., Akar, Z. A., Akkoc, R. F., Etem, E. O., Dagli, A. F., & Koca, S. S. (2022). Tofacitinib and metformin reduce the dermal thickness and fibrosis in mouse model of systemic sclerosis. Scientific Reports, 12(1), 2553. https://doi.org/10.1038/s41598-022-06581-1

Chicago

Karatas, Ahmet, Burak Oz, Cigdem Celik, Zeynel Abidin Akar, Ramazan Fazil Akkoc, Ebru Onalan Etem, Adile Ferda Dagli, and Suleyman Serdar Koca. 2022. “Tofacitinib and Metformin Reduce the Dermal Thickness and Fibrosis in Mouse Model of Systemic Sclerosis.” Scientific Reports 12 (1): 2553. doi:10.1038/s41598-022-06581-1.